2023
Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance.
Krykbaeva I, Bridges K, Damsky W, Pizzurro G, Alexander A, McGeary M, Park K, Muthusamy V, Eyles J, Luheshi N, Turner N, Weiss S, Olino K, Kaech S, Kluger H, Miller-Jensen K, Bosenberg M. Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance. Cancer Immunology Research 2023, 11: 1332-1350. PMID: 37478171, DOI: 10.1158/2326-6066.cir-22-0699.Peer-Reviewed Original ResearchConceptsPD-1 resistanceDendritic cellsTumor regressionAnti-PD-1 resistanceActivates Dendritic CellsCytokine secretion profilingSystemic cytokine profileTriple therapy combinationInnate immune activationAdaptive immune responsesComplete tumor regressionMajority of miceSignificant clinical challengeMouse melanoma modelT cell activationAgonistic CD40Checkpoint inhibitorsDC subsetsTriple therapyCytokine profileImmune activationCombinatorial immunotherapyTherapy combinationsT cellsClinical challenge
2021
Metabolism of Innate Immune Cells in Cancer
Talty R, Olino K. Metabolism of Innate Immune Cells in Cancer. Cancers 2021, 13: 904. PMID: 33670082, PMCID: PMC7927092, DOI: 10.3390/cancers13040904.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsInnate immune cellsImmune cellsAntitumor immune responseImmune checkpoint blockadeAdoptive cell transferOngoing clinical applicationsSpecific metabolic requirementsInnate immune systemCheckpoint blockadeTumor clearanceAntitumor responseImmune activationMetabolic requirementsT cellsImmune responseEffector functionsImmune systemCell transferTumor microenvironmentCancer cellsPrimary effectorClinical applicationCancerCellsMetabolism